3-azaniumyl-4-(4-phenylphenyl)butanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-azaniumyl-4-(4-phenylphenyl)butanoate
• 化学式: C16H17NO2
• 分子量: 255.31
• InChiKey: IHXITIQUZBCIHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• METHODS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125902A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及用于确定肾小球滤过率或评估患者肾功能的系统和方法。该方法包括向患者施用化合物I的吡嗪类化合物，并监测患者的肾脏从患者的全身循环中排除吡嗪的速率。当暴露于电磁辐射时，吡嗪化合物会发出荧光，使用一个或多个传感器来检测。患者体内荧光减少的速率被用来计算患者的肾小球滤过率。
• COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125901A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及确定肾小球滤过率或评估需要的患者的肾功能的系统和方法。该系统包括计算设备、电源、一个或多个传感器，以及至少一种示踪剂，当暴露于电磁辐射时发出荧光。传感器检测电磁辐射，患者体内荧光减弱的速率用于计算患者的肾小球滤过率。
• [EN] TRIAZINES DERIVATIVES AS CELL ADHESION INHIBITORS<br/>[FR] DERIVES DE TRIAZINES COMME INHIBITEURS DE L'ADHESION CELLULAIRE
  申请人：RANBAXY LAB LTD

  公开号：WO2005030735A1

  公开（公告）日：2005-04-07

  The present invention relates to triazine derivatives as cell adhesion inhibitors. The compounds of this invention can be useful inter alia, for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis. The compounds can be used to formulate pharmacological compositions, and the methods of treating bronchial asthma, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or autoimmune disorders, using the compounds are also provided herein.

  本发明涉及三嗪衍生物作为细胞黏附抑制剂。本发明的化合物可以用于抑制和预防细胞黏附和细胞黏附介导的病理反应，包括支气管哮喘、类风湿性关节炎、1型糖尿病、多发性硬化症、移植排斥、牛皮癣等炎性和自身免疫性疾病。这些化合物可以用于制备药物组合物，并且本文还提供了使用这些化合物治疗支气管哮喘、类风湿性关节炎、多发性硬化症、1型糖尿病、牛皮癣、移植排斥和其他炎性和/或自身免疫性疾病的方法。
• METHOD FOR PREPARING AND ANALYZING FLUORESCENT COMPOUNDS IN PLASMA
  申请人：MediBeacon, Inc.

  公开号：US20190154697A1

  公开（公告）日：2019-05-23

  Disclosed herein is a method for analyzing the concentration of a fluorescent compound in the plasma of a patient. The method includes collecting a sample of plasma from a patient, diluting the sample with a solvent and analyzing the diluted sample by HPLC. The sample does not need to be dried down during sample preparation nor is an internal standard required.

  本文公开了一种分析患者血浆中荧光化合物浓度的方法。该方法包括从患者采集血浆样本，用溶剂稀释样品并通过高效液相色谱分析稀释后的样品。在样品制备过程中，样品不需要干燥，也不需要内标。
• SUBCUTANEOUS AND INTRAMUSCULAR ADMINISTRATION OF PYRAZINE COMPOUNDS
  申请人：MediBeacon Inc.

  公开号：US20220143222A1

  公开（公告）日：2022-05-12

  The present disclosure relates to methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method comprises administering, subcutaneously or intramuscularly, a pyrazine compound of Formula I to a patient, wherein the administration produces a plasma concentration of the compound that is substantially similar to a plasma concentration produced by intravenous administration of an identical amount of the compound; and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which may be detected using one or more sensors. The rate in which the fluorescence decreases in the patient may be used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及用于确定患者的肾小球滤过率或评估其肾功能的方法。该方法包括将式I的吡嗪化合物经皮下或肌肉注射给予患者，其中给药产生的化合物血浆浓度与相同量的化合物经静脉注射产生的血浆浓度基本相似；并监测患者肾脏从全身循环中清除吡嗪的速率。当吡嗪化合物暴露于电磁辐射时，其会发出荧光，可以使用一个或多个传感器检测。患者体内荧光减少的速率可以用于计算患者的肾小球滤过率。